MedinCell announces participation in the Jefferies London Healthcare Conference 2021

MedinCell will be attending the 12th Jefferies London Healthcare Conference on Tuesday, November 16 and Wednesday, November 17 at the Waldorf Hilton in London.

The conference will be, notably, the opportunity for MedinCell to present to investors the findings of mdc-IRM’s Phase 3 which comprehensive analysis will be unveiled by MedinCell’s partner, Teva Pharmaceuticals, at Psych Congress (October 29 – November 1, San Antonio, USA).

mdc-IRM [Teva’s codename: TV46000], a subcutaneous risperidone injectable suspension for the treatment of patients with schizophrenia, is the most advanced investigational product based on MedinCell’s BEPO® technology. Ongoing New Drug Application review by FDA could lead to mdc-IRM commercialization as early as 2022 by Teva in the U.S., provided marketing authorization. MedinCell is eligible for development milestones, royalties on net sales and future commercial milestones.

MedinCell’s growing portfolio that includes many other long acting injectables from formulation to clinical stage in
different therapeutic areas. All investigational products aim at offering innovative therapeutic options that can
ensure patient compliance and adherence and improve efficiency and accessibility of treatments.